Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

Tokyo, Aug. 6 (Jiji Press)--A Japanese health ministry panel Wednesday approved a plan to cut the price of Lecanemab, an ...

Erin Kelly is likely going to forget her eight-year-old daughter Evie’s name before her little girl finishes high school.

Explore the growth potential of the Alzheimer's disease-modifying therapies (DMTs) market as lecanemab gains FDA approval in 2023. With several late- ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Four years of lecanemab treatment led to less cognitive decline and potentially even improvement in clinical scores over time ...

Differences in outcomes between patients with early Alzheimer’s disease who used lecanemab and matched controls increased ...

TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

A new Alzheimer’s drug, lecanemab, may slow disease progression and offer patients up to four extra years of stable health.